A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Troriluzole (Primary)
- Indications Spinocerebellar ataxias
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
- 18 Nov 2019 Planned number of patients changed from 230 to 210.
- 07 May 2019 According to a Biohaven Pharmaceuticals media release, company expects to complete enrollment in the first quarter of 2020.
- 14 Mar 2019 According to Biohaven Pharmaceuticals media release, first patient has been enrolled in this study.